Mark Avagliano is Vice President of Corporate Development at Pfizer, responsible for evaluating, planning and executing large-scale corporate level transactions, including acquisitions, joint ventures and divestitures.
Mark joined Pfizer in 2004 from Aventis Pharmaceuticals and has over 17 years pharmaceuticals industry experience. Prior to his current role, Mark worked in various transactional, financial and commercial areas, including business development, portfolio and decision analysis, new products commercialization and sales and marketing operations.
Mark earned a master’s degree in Finance and Accounting from the London School of Economics, a master’s degree in Comparative Social Policy from Oxford University, and a bachelor’s degree in Mathematics and Political Science from Marist College. Mark also is a Board member of Charley’s Fund, a non-profit organization focused on supporting and accelerating research and development for new treatments for Duchenne Muscular Dystrophy (DMD).